• Mashup Score: 0

    September 27, 2023 — Boston Scientific announced the FDA clearance of the AVVIGOTM+ Multi-Modality Guidance System, a next-generation intravascular ultrasound (IVUS)1 and fractional flow reserve (FFR)2 system with advanced software and hardware features designed to provide high-quality IVUS vessel imaging and physiology experience during percutaneous coronary intervention (PCI) procedures. Building upon the AVVIGO Guidance System II, this technology helps to inform treatment decisions and enable faster, more efficient treatment procedures such as angioplasties3 and atherectomies for patients with coronary artery disease. The company also recently received CE Mark, with launch anticipated early next year.  Key features of the AVVIGO+ system include:  First IVUS system with an artificial intelligence (AI) software called Automated Lesion Assessment to automate key procedural steps and provide precise vessel measurements  Reduces procedure time significantly by acquiring IVUS images at a

    Tweet Tweets with this article
    • @DAICeditor @bostonsci #BostonScientific announced the #FDA clearance of the #AVVIGOTM+ Multi-Modality Guidance System, a next-generation #intravascular_ultrasound (#IVUS) and fractional flow reserve (#FFR) system: https://t.co/37R9V5fmuS

  • Mashup Score: 0

    Objectives To evaluate the impact of introducing CT fractional flow reserve (FFRCT) on stable chest pain pathways, concordance with National Institute for Health and Care Excellence (NICE) chest pain guidelines, resource usage and revascularisation of patients from a tertiary UK cardiac centre rapid access chest pain clinic (RACPC). Methods Single-centre before and after study comparing data…

    Tweet Tweets with this article
    • Impact on stable chest pain pathways of CT fractional flow reserve https://t.co/lMLQQsYeHT #CTCA #FFR #FFRct #cardiotwitter @HeartFlow via @Heart_BMJ @doctorradiology https://t.co/xqeJ93AboA